Non-Hispanic Black Persons With Nonalcoholic Fatty Liver Disease Have Lower Rates of Advanced Fibrosis, Cirrhosis, and Liver-Related Events Even After Controlling for Clinical Risk Factors and PNPLA3 Genotype
- PMID: 38483303
- PMCID: PMC11399313
- DOI: 10.14309/ajg.0000000000002756
Non-Hispanic Black Persons With Nonalcoholic Fatty Liver Disease Have Lower Rates of Advanced Fibrosis, Cirrhosis, and Liver-Related Events Even After Controlling for Clinical Risk Factors and PNPLA3 Genotype
Abstract
Introduction: Nonalcoholic fatty liver disease (NAFLD) is less frequent in non-Hispanic persons (NHB), but there are knowledge gaps in our understanding of disease severity and outcomes of NAFLD in NHB. We compared liver histology and clinical outcomes of NAFLD in non-Hispanic Black persons (NHB) and non-Hispanic White persons (NHW).
Methods: We compared liver histology and outcomes of 109 NHB and 1,910 NHW adults with biopsy-proven NAFLD participating in the Nonalcoholic Steatohepatitis Clinical Research Network observational studies. The relationship between self-reported NHB race/ethnicity and advanced fibrosis was assessed through multivariable logistic regression after controlling for clinical covariates and PNPLA3 genotype.
Results: NHB and NHW with NAFLD had similar NAFLD activity scores (NAS, 4.4 vs 4.3, P = 0.87) and proportions with definite metabolic dysfunction-associated steatohepatitis (59% vs 58%, P = 1.0), but NHB had significantly lower rates of advanced fibrosis (22% vs 34%, P = 0.01) or cirrhosis (4.6% vs 12.1%, P = 0.010). Compared with NHW, NHB had significantly lower frequency of advanced fibrosis (Odds Ratio: 0.48, 95% Confidence Interval: 27-0.86, P = 0.01). In a comparison between 24 NHB and 655 NHW with advanced fibrosis, the NAS (5.6 vs 4.9, P = 0.01) and lobular inflammation grade (2.2 vs 1.7, P < 0.002) were significantly higher among NHB with advanced fibrosis. One NHB and 23 NHW died during follow-up (0.30 vs 0.28 per 100 person-year follow-up). Seven and zero liver-related deaths occurred in NHW and NHB with NAFLD, respectively.
Discussion: The risk of advanced fibrosis in NHB with NAFLD is significantly lower, after controlling for clinical risk factors and PNPLA3 genotype. Although their risk of advanced fibrosis was low, NHB with NAFLD and advanced fibrosis had higher NAS and lobular inflammation, indicating a difference in their relationship between necroinflammation and fibrosis.
Copyright © 2024 by The American College of Gastroenterology.
Conflict of interest statement
Conflicts of Interest
Drs. Samala and Hoofnagle, Laura Wilson, Katherine Yates and Yuchen Xin report no conflicts of interest.
Similar articles
-
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.Clin Gastroenterol Hepatol. 2024 May;22(5):1024-1036.e2. doi: 10.1016/j.cgh.2023.12.009. Epub 2023 Dec 23. Clin Gastroenterol Hepatol. 2024. PMID: 38145725
-
Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.Clin Res Hepatol Gastroenterol. 2024 Aug;48(7):102389. doi: 10.1016/j.clinre.2024.102389. Epub 2024 Jun 1. Clin Res Hepatol Gastroenterol. 2024. PMID: 38830575
-
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.Hepatol Commun. 2022 Oct;6(10):2689-2701. doi: 10.1002/hep4.2032. Epub 2022 Jul 14. Hepatol Commun. 2022. PMID: 35833455 Free PMC article.
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Interventions for supporting pregnant women's decision-making about mode of birth after a caesarean.Cochrane Database Syst Rev. 2013 Jul 30;2013(7):CD010041. doi: 10.1002/14651858.CD010041.pub2. Cochrane Database Syst Rev. 2013. PMID: 23897547 Free PMC article. Review.
Cited by
-
Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization.Healthcare (Basel). 2024 Jul 25;12(15):1478. doi: 10.3390/healthcare12151478. Healthcare (Basel). 2024. PMID: 39120181 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR002649/TR/NCATS NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- UL1 TR000006/TR/NCATS NIH HHS/United States
- UL1 TR000436/TR/NCATS NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- UL1 TR002345/TR/NCATS NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U24 DK061730/DK/NIDDK NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- grants U01DK061713, U01DK061718, U01DK061728, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U24DK061730). Additional support is received from the National Center for Advancing Translational Sciences (NCATS) (grants UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR002649/DK/NIDDK NIH HHS/United States
- UL1 TR000423/TR/NCATS NIH HHS/United States
- UL1 TR000100/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical